Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking
- PMID: 28623421
- DOI: 10.1007/s10067-017-3729-z
Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking
Abstract
Tophaceous gout is painful and impairs quality of life. The optimal modality for assessing tophus resolution in response to urate-lowering treatment remains poorly defined. Using pegloticase as a model system for resolving tophi, we compared multiple imaging and physical diagnostic strategies for assessing tophus resolution. A 32-year-old subject with chronic refractory tophaceous gout was enrolled and received 6 months of pegloticase treatment. Measurements of tophi using vernier calipers (monthly), photographs and musculoskeletal ultrasound (MSK-US; every 3 months), and dual-energy CT (DECT) were compared. Pegloticase persistently lowered the patient's sUA to <0.5 mg/dl. After 6 months, caliper measurements revealed 73, 60, and 61% reductions of three index tophi, while MSK-US revealed 47, 65, and 48% reductions. In contrast, DECT revealed 100% resolution of monosodium urate deposition in all three index tophi, and resolution or improvement of all other tophi identified. On caliper and MSK-US measurement, index tophus size fluctuated, with some lesions enlarging before ultimately contracting. Correlation between assessment modalities during tophus resolution may be poor. DECT identifies urate deposits invisible to physical exam and reveals that some urate deposits completely resolve even as their physically/sonographically measurable lesions persist. Recognition of urate resorption during the urate-lowering process may be confounded by fluctuating lesion volumes during initial tophus breakdown. While DECT was superior for identifying total (including occult) urate deposition, and assessing volume of deposits, other modalities may permit better assessment of non-urate tophus components.
Keywords: Dual-energy CT; Gout; Pegloticase; Ultrasound; Uric acid.
Similar articles
-
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.Arthritis Res Ther. 2018 Dec 29;20(1):286. doi: 10.1186/s13075-018-1782-x. Arthritis Res Ther. 2018. PMID: 30594229 Free PMC article.
-
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318. Arthritis Res Ther. 2013. PMID: 24286509 Free PMC article. Clinical Trial.
-
Assessment of tophus size: a comparison between physical measurement methods and dual-energy computed tomography scanning.J Clin Rheumatol. 2012 Jan;18(1):23-7. doi: 10.1097/RHU.0b013e31823e5cda. J Clin Rheumatol. 2012. PMID: 22157268
-
Pegloticase for treating refractory chronic gout.Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475. Drugs Today (Barc). 2012. PMID: 22844655 Review.
-
Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.Semin Arthritis Rheum. 2020 Jun;50(3S):S31-S38. doi: 10.1016/j.semarthrit.2020.04.011. Semin Arthritis Rheum. 2020. PMID: 32620200 Review.
Cited by
-
Current status of ultrasound and dual-energy computed tomography in the evaluation of gout.Rheumatol Int. 2018 Aug;38(8):1339-1344. doi: 10.1007/s00296-018-4033-1. Epub 2018 May 2. Rheumatol Int. 2018. PMID: 29721694 Review.
-
Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.Ther Adv Drug Saf. 2017 Dec;8(12):379-388. doi: 10.1177/2042098617727714. Epub 2017 Sep 13. Ther Adv Drug Saf. 2017. PMID: 29204266 Free PMC article. Review.
-
Mechanisms and rationale for uricase use in patients with gout.Nat Rev Rheumatol. 2023 Oct;19(10):640-649. doi: 10.1038/s41584-023-01006-3. Epub 2023 Sep 8. Nat Rev Rheumatol. 2023. PMID: 37684360 Review.
-
Gout of hand and wrist: the value of US as compared with DECT.Eur Radiol. 2018 Oct;28(10):4174-4181. doi: 10.1007/s00330-018-5363-9. Epub 2018 Apr 20. Eur Radiol. 2018. PMID: 29679210 Free PMC article.
-
Prevalence and Risk Factors for Peripheral Neuropathy in Chinese Patients With Gout.Front Neurol. 2022 Feb 24;13:789631. doi: 10.3389/fneur.2022.789631. eCollection 2022. Front Neurol. 2022. PMID: 35280274 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical